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Summary
Background After breast-conserving surgery, 90% of local recurrences occur within the index quadrant despite the 
presence of multicentric cancers elsewhere in the breast. Thus, restriction of radiation therapy to the tumour bed during 
surgery might be adequate for selected patients. We compared targeted intraoperative radiotherapy with the conventional 
policy of whole breast external beam radiotherapy.
Methods Having safely piloted the new technique of single-dose targeted intraoperative radiotherapy with Intrabeam, 
we launched the TARGIT-A trial on March 24, 2000. In this prospective, randomised, non-inferiority trial, women 
aged 45 years or older with invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled 
from 28 centres in nine countries. Patients were randomly assigned in a 1:1 ratio to receive targeted intraoperative 
radiotherapy or whole breast external beam radiotherapy, with blocks stratiﬁ ed by centre and by timing of delivery of 
targeted intraoperative radiotherapy. Neither patients nor investigators or their teams were masked to treatment 
assignment. Postoperative discovery of predeﬁ ned factors (eg, lobular carcinoma) could trigger addition of external 
beam radiotherapy to targeted intraoperative radiotherapy (in an expected 15% of patients). The primary outcome was 
local recurrence in the conserved breast. The predeﬁ ned non-inferiority margin was an absolute diﬀ erence of 2·5% 
in the primary endpoint. All randomised patients were included in the intention-to-treat analysis. This trial is 
registered with ClinicalTrials.gov, number NCT00983684.
Findings 1113 patients were randomly allocated to targeted intraoperative radiotherapy and 1119 were allocated to 
external beam radiotherapy. Of 996 patients who received the allocated treatment in the targeted intraoperative 
radiotherapy group, 854 (86%) received targeted intraoperative radiotherapy only and 142 (14%) received targeted 
intraoperative radiotherapy plus external beam radiotherapy. 1025 (92%) patients in the external beam radiotherapy 
group received the allocated treatment. At 4 years, there were six local recurrences in the intraoperative radiotherapy 
group and ﬁ ve in the external beam radiotherapy group. The Kaplan-Meier estimate of local recurrence in the 
conserved breast at 4 years was 1·20% (95% CI 0·53–2·71) in the targeted intraoperative radiotherapy and 0·95% 
(0·39–2·31) in the external beam radiotherapy group (diﬀ erence between groups 0·25%, –1·04 to 1·54; p=0·41). The 
frequency of any complications and major toxicity was similar in the two groups (for major toxicity, targeted 
intraoperative radiotherapy, 37 [3·3%] of 1113 vs external beam radiotherapy, 44 [3·9%] of 1119; p=0·44). Radiotherapy 
toxicity (Radiation Therapy Oncology Group grade 3) was lower in the targeted intraoperative radiotherapy group (six 
patients [0·5%]) than in the external beam radiotherapy group (23 patients [2·1%]; p=0·002).
Interpretation For selected patients with early breast cancer, a single dose of radiotherapy delivered at the time of 
surgery by use of targeted intraoperative radiotherapy should be considered as an alternative to external beam 
radiotherapy delivered over several weeks.
Funding University College London Hospitals (UCLH)/UCL Comprehensive Biomedical Research Centre, UCLH 
Charities, National Institute for Health Research Health Technology Assessment programme, Ninewells Cancer 
Campaign, National Health and Medical Research Council, and German Federal Ministry of Education and 
Research (BMBF).
Introduction
During the past 50 years, the conceptual approach to breast 
cancer treatment has shifted from radical mastectomy1 to 
local treatment that preserves the breast and axillary lymph 
nodes along with adjuvant systemic therapy. Breast-
conserving surgery followed by post operative whole breast 
external beam radiotherapy is now the standard of care for 
suitable patients with early breast cancer.
External beam radiotherapy is a safe and eﬀ ective 
treatment; the risk of side-eﬀ ects is low, but since breast 
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cancer is common, the absolute number of women with 
complications and side-eﬀ ects is large. More importantly, 
the 3–7 weeks of a typical postoperative radiotherapy 
schedule is at best inconvenient for working women or 
exhausting and often untenable for elderly women. 
Although many studies2–4 have failed to identify a 
subgroup of patients in whom radiotherapy can be 
completely avoided, whether irradiation of the whole 
breast is necessary in all or a subgroup of patients 
remains unclear.
Many observational studies and randomised clinical 
trials have shown that more than 90% of recurrent 
disease occurring in the breast is within the index 
quadrant,5–13 which is by contrast with the ﬁ ndings of 
three-dimensional analysis of mastectomy specimens 
that show that 63% of breasts harbour occult cancer foci, 
with 80% of these situated remote from the index 
quadrant.14–16 These widespread and occult multifocal or 
multicentric cancers in other quadrants of the breast 
therefore appear to remain dormant for many years or 
even decades, and have a low risk of causing clinical 
tumours. Thus, irradiation of the immediate vicinity of 
the primary tumour might be adequate for achieving 
local control of cancer.14–16
The TARGIT-A trial was designed to test the hypothesis 
that in selected patients, substituting the policy of whole 
breast radiotherapy after breast-conserving surgery with 
a policy of targeted intraoperative radiotherapy (also 
known as TARGIT) to the tumour bed with additional 
whole breast radiotherapy in a subgroup of patients 
(around 15%) with poor features on ﬁ nal pathology would 
not lead to inferior local control of breast cancer.
Methods
Study design and participants
TARGIT-A was a pragmatic, prospective, international, 
multicentre, randomised, phase 3 trial that compared 
targeted intraoperative radiotherapy with the 
conventional policy of whole breast external beam 
radiotherapy. An outline of the protocol and the full 
protocol are available online. Women with early breast 
cancer were eligible for enrolment if they were aged 
45 years or older and were suitable for wide local excision 
for invasive ductal carcinoma that was unifocal on 
conventional examination and imaging (MRI was not 
necessary for conﬁ rming unifocality). Preoperative 
diagnosis of lobular carcinoma was an exclusion 
criterion. Patients gave written informed consent to join 
the trial. The protocol was approved by the appropriate 
regulatory and ethics authorities for each centre before 
enrolment could begin.
The initial trial plan was developed in University College 
London (UCL), London, UK. Management of the trial 
was coordinated and supervised by the international 
steering committee (ISC) with advice from the data 
monitoring committee (DMC). Representatives from 
the manufacturer of the Intrabeam equipment (Carl 
Zeiss, Oberkochen, Germany) attended the ISC 
meetings as observers. The trial statistician supervised 
all data analyses. The interpretation of the analyses, 
presentation of data at meetings, and preparation of 
manuscripts for publication are all responsibilities of 
the ISC. The TARGIT Trials Operations Oﬃ  ce is located 
at UCL and is responsible for randomisations, data 
collection, data management, and servicing of the ISC 
and DMC. No changes were made to the methods after 
commencement of the trial.
Before centres were allowed to participate, the team 
was trained and audited by a member of the ISC. Each 
centre was allowed to restrict the inclusion criteria 
beyond the core protocol, and to stipulate local policy for 
giving external beam radiotherapy (typically 40–56 Gy 
with or without a boost of 10–16 Gy, standard tangents, 
etc) both in the external beam radiotherapy group and as 
an additional dose in the targeted intraoperative 
radiotherapy group, in a site-speciﬁ c treatment policy 
document that was reviewed and signed oﬀ  by the ISC 
before randomisation could begin.
BA
Figure 1: Targeted intraoperative radiotherapy technique with the Intrabeam system
(A) The applicator being placed in the tumour bed. (B) The x-ray source is delivered to the tumour bed by use of a surgical support stand. The sterile applicator is 
joined with a sterile drape that is used to cover the stand during treatment delivery.
For an outline of the protocol 
for this trial see http://www.
thelancet.com/
protocol-reviews/99PRT-47 
For the full protocol for this 
trial see http://www.hta.ac.uk/
project/1981.asp
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Procedures
The concept and technique of targeted intraoperative 
radiotherapy, which was pioneered by our group,17–19 is 
designed to allow the patient to receive all required 
radiation in a single fraction before she awakes from 
surgery. The clinicopathological rationale, the 
technology of the device, surgical technique (ﬁ gure 1), 
radiobiology, and acute and long-term toxicity have been 
previously described.5,14–24
Brieﬂ y, the Intrabeam device provides a point source 
of low energy x-rays (50 kV maximum) at the tip of a 
3·2 mm diameter tube that is placed at the centre of a 
spherical tumour bed applicator. After surgically 
positioning the appropriately sized applicator in the 
tumour bed, radiation is switched on for 20–35 min to 
target the tissues that are at highest risk of local 
recurrence. The surface of the tumour bed typically 
receives 20 Gy that attenuates to 5–7 Gy at 1 cm depth. 
We established the safety and tolerability of the 
technique in phase 2 studies started in July, 1998,17,20 in 
which targeted intraoperative radiotherapy was 
delivered as a substitute for tumour bed boost, followed 
by standard external beam radiotherapy to the whole 
breast. The most recent update, in 300 patients, has a 
median follow-up of 60·5 months and the 5-year 
Kaplan-Meier estimate for ipsilateral recurrence was 
1·74% (SE 0·77).25
In this trial, we compared the conventional policy of 
whole breast external beam radiotherapy with the 
experimental policy of targeted intraoperative 
radiotherapy given in a single dose. We recognised that 
because of unfavourable features found subsequently in 
the pathological examination of the excised lesion (eg, 
lobular carcinoma), some patients (around 15%) assigned 
to targeted intraoperative radiotherapy will need to have 
external beam therapy in addition (without the boost that 
would already have been provided by the targeted 
intraoperative dose).
For more information about 
targeted intraoperative 
radiotherapy see http://www.
targit.org.uk
Breast cancer patient suitable for breast-conserving therapy
Adjuvant systemic treatment as appropriate; regular follow-up
Wide local excision of primary tumour plus deﬁnitive sentinel
node biopsy and/or axillary dissection
Histopathology shows involved margins
but no other adverse criteria
Histopathology shows (a) invasive lobular
carcinoma, (b) extensive intraductal
component, or (c) an adverse criterion*
Agreement to re-excise to clear margins
Randomisation
EBRT groupTARGIT group
Conventional course of postoperative EBRT 
to the whole breast with or without tumour 
bed boost
If necessary, re-excise for clear margins; 
TARGIT
Give appropriate
management but
exclude from trial
No Yes
Breast cancer patient suitable for breast-conserving therapy
Randomisation
TARGIT group EBRT group
Wide local excision of primary tumour plus deﬁnitive
sentinel node biopsy and/or axillary dissection plus TARGIT
Wide local excision of 
primary tumour plus 
deﬁnitive sentinel node 
biopsy and/or axillary
dissection
Histopathology
shows no 
adverse criteria
Histopathology
shows
(a) invasive
lobular
carcinoma,
(b) extensive 
intraductal 
component, or 
(c) an adverse 
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Histopathology
shows involved 
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If necessary re-excision
to achieve clear margins
Re-excise to
clear margins
No further local
treatment
Whole breast radiotherapy omitting
the tumour bed boost
Conventional course of
postoperative EBRT to the 
whole breast with or 
without tumour bed 
boost
Adjuvant systemic treatment as appropriate, regular follow-up
BA
Figure 2: Randomisation strata
TARGIT=targeted intraoperative radiotherapy. EBRT=external beam radiotherapy. (A) Prepathology entry. Randomisation was done before the deﬁ nitive surgical removal of the tumour. Characteristics 
that would prompt addition of EBRT were predeﬁ ned (eg, unexpected lobular carcinoma, extensive intraductal component, positive margins at ﬁ rst excision, in addition to others by individual centre). 
(B) Postpathology entry/TARGIT as a second procedure. Postpathology entry allowed for patients randomised for entry to the trial only once the pathological characteristics of the tumour had been 
reported. If allocated to TARGIT the wound was opened, the applicator inserted, and TARGIT given as a second surgical procedure. *Decided by each centre at the outset—eg, grade 3, node 
involvement, lymphovascular invasion.
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Randomisation and masking
The randomisation schedules were generated centrally 
by computer (securely kept in trial centres in Perth for 
Australian centres and London, UK, for all other centres). 
Requests for randomisation were via telephone or fax to 
the trials oﬃ  ce (Perth or London), where a trained 
member of staﬀ  checked patient eligibility. Treatment 
was allocated from a pre-printed randomisation schedule 
available to authorised staﬀ  only. Written conﬁ rmation of 
randomisation was sent by fax to the site. Patients were 
randomly assigned in a 1:1 ratio to receive targeted 
intraoperative radiotherapy or external beam radiotherapy, 
with blocks stratiﬁ ed by centre and by timing of delivery 
of targeted intraoperative radiotherapy. Three strata were 
used to stratify patients by timing of delivery. Details of 
the ﬁ rst two strata (prepathology entry and postpathology 
entry/targeted intraoperative radiotherapy as a second 
procedure) are given in ﬁ gure 2.
If a patient otherwise suitable for the TARGIT-A trial 
was found to have a history of previous contralateral breast 
cancer, we did not exclude them. Such patients were 
expected to be few and we wished to ensure that their 
distribution between the two groups remained balanced. 
Hence they were randomised in a third stratum.
Neither patients nor investigators or their teams were 
masked to treatment given after randomisation. Individual 
sites were unblinded to treatment given to their own 
patients, but they were not given access to these data for 
other sites. Conﬁ dential unblinded reports for the DMC, 
and blinded reports for the ISC were produced by the trial 
statistician. Unblinded analyses were done according to a 
prespeciﬁ ed statistical analysis plan.
Outcomes
Patients’ assessments were scheduled at entry, 3 months, 
and 6 months; thereafter, they were scheduled every 
6 months up to 5 years, and then yearly for up to 10 years.
The primary outcome of the trial was pathologically 
conﬁ rmed local recurrence in the conserved breast. The 
secondary outcome measure of local toxicity or morbidity 
was assessed from data recorded on the complications 
form, which contained a prespeciﬁ ed checklist: 
Prepathology Postpathology Contralateral Total
University College London, London, UK 144 29 10 183
Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Germany 145 0 7 152
Sir Charles Gairdner Hospital, Perth, WA, Australia 34 246 7 287
Centro di Riferimento Oncologico, Aviano, Italy 219 4 16 239
Ninewells Hospital, Dundee, UK 129 34 6 169
University of California, San Francisco, CA, USA 78 12 3 93
Frauenklinik vom Roten Kreuz, Munich, Germany 195 0 5 200
University of Southern California, Los Angeles, CA, USA 51 10 7 68
Ospedale San Giuseppe di Empoli, Empoli, Italy 53 1 0 54
Sankt Gertrauden-Krankenhaus, Berlin, Germany 47 0 0 47
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 0 9 0 9
Ludwig Maximilians Universität, Munich, Germany 68 0 1 69
Universität Frankfurt am Main, Frankfurt, Germany 33 0 2 35
Herlev/Rigs Hospitals, Copenhagen, Denmark 0 292 10 302
Medical University of Lublin, Lublin, Poland 41 0 0 41
Royal Free/Whittington Hospitals, London, UK 49 4 0 53
Lafayette Surgical Clinic, Lafayette, IN, USA 4 6 2 12
Sentara Surgery Specialists, Hampton, VA, USA 8 0 0 8
Uniklinikum des Saarlandes, Homburg, Germany 46 0 1 47
Princess Margaret Hospital, Toronto, ON, Canada 13 0 0 13
Royal Hampshire County Hospital, Winchester, UK 50 10 0 60
Brust Zentrum Seefeld, Zurich, Switzerland 26 0 0 26
Universitäts Spital Zurich, Zurich, Switzerland 14 0 0 14
St Olav’s Hospital, Trondheim, Norway 20 0 1 21
University of Nebraska Medical Center, Omaha, NE, USA 0 11 0 11
Guy’s Hospital, London, UK 0 4 0 4
Poughkeepsie, NY, USA 12 0 0 12
Dobbs Ferry, NY, USA 3 0 0 3
Total 1482 672 78 2232
Centres are listed in the order that they joined the trial. The patients randomised from each country were: UK 469 (21%), Germany 571 (26%), Denmark 302 (14%), Australia 
296 (13%), Italy 293 (13%), USA 207 (9%), Poland 41 (2%), Switzerland 40 (2%), Canada 13 (1%).
Table 1: International centres and accrual in the three main strata, by site and country
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haematoma, seroma, wound infection, skin breakdown, 
delayed wound healing, Radiation Therapy Oncology 
Group (RTOG version 2.0) toxicity grade 3 or 4 for 
dermatitis, telangiectasia, pain in irradiated ﬁ eld, or 
other. We analysed seroma needing more than three 
aspirations, wound infections needing intravenous 
antibiotics, any complication needing surgical 
intervention, or (RTOG) toxicity grade more than 2. Skin 
breakdown or delayed wound healing or RTOG grade 
more than 2 were classiﬁ ed as major toxicity.
To compare the extent of local surgery we analysed the 
specimen weight, margin status, and re-operation for 
margins. No changes were made to trial outcomes after 
commencement of the trial.
Statistical analysis
The predeﬁ ned non-inferiority margin was an absolute 
diﬀ erence of 2·5% in the primary endpoint between 
groups. To test for non-inferiority with a background 
5-year recurrence rate of 6%12,26 and an absolute non-
inferiority margin of 2·5%, a total sample size of 
2232 patients was calculated for 80% power at a 5% 
signiﬁ cance level.
The analysis was done in accordance with the 
CONSORT guidelines.27 Data lock was on May 2, 2010. 
All randomised patients were included in the intention-
to-treat analysis, which compared the targeted 
intraoperative radiotherapy group with the external 
beam radiotherapy group, for eﬃ  cacy and safety of the 
strategy. For the analysis of local recurrence in the 
conserved breast, patients who underwent mastectomy 
as their deﬁ nitive surgery (for reasons such as positive 
margins, patient choice, etc) and patients who died or 
withdrew consent for further follow-up were censored 
on that date. All other recurrences in the conserved 
breast, but not axilla, were analysed and Kaplan-Meier 
curves were plotted to account for time to event and 
censoring of the data and included all patients. We also 
analysed the annual hazards of local recurrence in the 
conserved breast. When displaying the results, we 
2232 patients enrolled and randomised
1113 assigned to TARGIT with or 
           without EBRT
4 withdrawn
13 unknown
100 did not receive
allocated treatment
61 received EBRT
31 had mastectomy
8 received wide local 
excision only
996 received allocated
treatment
854 received TARGIT only
142 received  TARGIT
and EBRT
1113 included in analysis 1119 included in analysis
66 did not receive
allocated treatment
10 received TARGIT
4 received TARGIT and
EBRT
30 had mastectomy
22 received wide local
excision only
1025 received allocated
treatment
11 withdrawn
17 unknown
1119 assigned to EBRT
Figure 3: Trial proﬁ le
TARGIT=targeted intraoperative radiotherapy. EBRT=external beam 
radiotherapy. Data for number of patients screened for eligibility are not 
available from all centres.
Targeted intraoperative 
radiotherapy (n=1113)
External beam radiotherapy 
(n=1119)
Age (years)
<45 17/1113 (2%) 10/1119 (1%)
45–54 212/1113 (19%) 167/1119 (15%)
55–64 443/1113 (40%) 464/1119 (41%)
65–74 355/1113 (32%) 381/1119 (34%)
>74 86/1113 (8%) 97/1119 (9%)
Height (cm) 164 (159–168) 163 (159–168)
Weight (kg) 70 (62–80) 70 (62–80)
Pathological tumour size (cm)
<1 381/1056 (36%) 388/1061 (37%)
1–2 531/1056 (50%) 519/1061 (49%)
>2 144/1056 (14%) 154/1061 (15%)
Unknown 57/1113 (5%) 58/1119 (5%)
Tumour type
Invasive ductal carcinoma 1012/1070 (95%) 1018/1079 (94%)
Invasive lobular carcinoma 47/1070 (4%) 45/1079 (4%)
Mixed 32/1070 (3%) 35/1079 (3%)
Unknown 43/1113 (4%) 40/1119 (4%)
Tumour grade
1 341/1040 (33%) 374/1048 (36%)
2 540/1040 (52%) 514/1048 (49%)
3 159/1040 (15%) 160/1048 (15%)
Unknown 73/1113 (7%) 71/1119 (6%)
Lymphovascular invasion
Absent 881/1022 (86%) 894/1026 (87%)
Present 141/1022 (14%) 132/1026 (13%)
Unknown 91/1113 (8%) 93/1119 (8%)
Ductal carcinoma in situ
Present 529/1063 (50%) 547/1069 (51%)
Absent 534/1063 (50%) 522/1069 (49%)
Unknown 50/1113 (4%) 50/1119 (4%)
Nodes involved
0 866/1059 (82%) 898/1070 (84%)
1–3 155/1059 (15%) 149/1070 (14%)
>3 38/1059 (4%) 23/1070 (2%)
Unknown 54/1113 (5%) 49/1119 (4%)
Hormone receptors
Oestrogen-receptor positive 962/1063 (90%) 981/1060 (93%)
Oestrogen-receptor negative 101/1063 (10%) 79/1060 (7%)
Oestrogen-receptor status unknown 50/1113 (4%) 59/1119 (5%)
(Continues on next page)
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restricted the duration to 4 years as recommended by 
Pocock and colleagues,28 since fewer than 420 (<20%) 
patients had a follow-up beyond this point. The 
customised trial database was in Microsoft Access 2003; 
SAS System version 9.2 for Windows XP and STATA 
version 11.0 were used for data compilation and analysis. 
Pearson χ² test and log-rank test were used to obtain 
p values.
This trial is registered with ClinicalTrials.gov, number 
NCT00983684.
Role of the funding source
This was an academically driven trial. The funding bodies 
had no role in trial design, data analysis, data 
interpretation, or writing of the report. Carl Zeiss has 
partly supported a few centres for help in data collection. 
The corresponding author had full access to all data in 
the study. All authors had ﬁ nal responsibility for the 
decision to submit for publication.
Results
The ﬁ rst patient was randomised on March 24, 2000, and 
the trial recruited patients from 28 centres in nine 
countries. 1113 patients were randomly allocated to 
targeted intraoperative radiotherapy and 1119 were 
allocated to external beam radiotherapy. Table 1 shows 
the distribution of patients in individual sites and strata.
Figure 3 shows the trial proﬁ le. 89% of patients in 
the targeted intraoperative radiotherapy group and 
92% in the external beam radiotherapy group received 
the allocated treatment. Of those who received the 
allocated treatment in the targeted intraoperative 
radio therapy group, 86% received targeted 
intraoperative radiotherapy only and 14% received 
targeted intra operative radiotherapy plus external 
beam radiotherapy (ﬁ gure 3), matching the 15% 
expectation in the protocol.
Follow-up information was available for 1668 (99%) 
patients randomised before May 2, 2009, and 1945 (98%) 
patients randomised before Nov 2, 2009, 12 months and 
6 months before the data lock, respectively.
Table 2 shows patient and tumour characteristics. 
The median age was 63 years (IQR 57–69) and 1834 
(82%) patients were younger than 70 years. Tumour 
sizes were small: 36% were less than 1 cm, 50% were 
between 1 cm and 2 cm, and 14% were more than 2 cm. 
Most tumours were grade 1 (34%) or 2 (50%); only 15% 
were grade 3. Nodes were uninvolved in 83% of 
patients. 66% of systemic therapy was hormonal and 
12% was chemotherapy.
Table 3 shows that the median amount of tissue excised 
during breast-conserving surgery was similar in the two 
groups, as was the proportion of ﬁ rst excisions with free 
margins. The diﬀ erence in re-excision rates was not 
signiﬁ cant between the two main strata (prepathology 
119 [7·8%] vs postpathology 63 [9·0%], p=0·31) or between 
the two groups (table 3; p=0·07).
The number of patients with any complication (table 4) 
was similar in the two groups. Table 5 shows the clinically 
Targeted intraoperative 
radiotherapy (n=1113)
External beam radiotherapy 
(n=1119)
(Continued from previous page)
HER2 (ERBB2) receptor status
Positive 132/991 (13%) 132/1004 (13%)
Negative 859/991 (87%) 872/1004 (87%)
Not done 31/1113 (3%) 33/1119 (3%)
Unknown 91/1113 (8%) 82/1119 (7%)
Adjuvant therapy
Hormone therapy 727/1113 (65%) 753/1119 (67%)
Chemotherapy 116/1113 (10%) 141/1119 (13%)
Other 48/1113 (4%) 41/1119 (4%)
Unknown 100/1113 (9%) 89/1119 (8%)
Data are n/N (%) or median (IQR). The denominator for unknown percentages is the number of randomised patients 
and the denominator for each category is the number of known cases. Percentages are rounded, so may not add up to 
100%.
Table 2: Patient and tumour characteristics
Targeted intraoperative radiotherapy External beam radiotherapy
Specimen weight (g)* 46 (28–72) 47 (29–76)
Margins at ﬁ rst excision
Free 970/1072 (90·5%) 968/1073 (90·2%)
DCIS only 46/1072 (4·3%) 43/1073 (4·0%)
Invasive 56/1072 (5·2%) 62/1073 (5·8%)
Unknown 41/1113 (3·7%) 46/1119 (4·1%)
Re-excision for margins
Prepathology stratum 52/766 (6·8%) 67/768 (8·72%)
Postpathology stratum 27/347 (7·8%) 36/351 (10·3%)
Total 79/1113 (7·1%) 103/1119 (9·2%)
Data are median (IQR) or n/N (%). DCIS=ductal carcinoma in situ. *Specimen weight was available for 1219 patients 
(targeted intraoperative therapy, n=614; external beam radiotherapy, n=605). The denominator for unknown 
percentages is the number of randomised patients and the denominator for each category is the number of known 
cases.
Table 3: Extent of surgery
Targeted intraoperative 
radiotherapy (n=1113)
External beam 
radiotherapy (n=1119)
Number of complications per patient
0 917 (82·4%) 946 (84·5%)
1 151 (13·6%) 139 (12·4%)
2 29 (2·6%) 27 (2·4%)
3 11 (1·0%) 5 (0·4%)
4 3 (0·3%) 0
5 2 (0·2%) 0
6 0 3 (0·3%)
Any complication* 196 (17·6%) 174 (15·5%)
Data are number of patients (%). *χ2 1·74, p=0·19 comparison between the 
targeted intraoperative radiotherapy and external beam radiotherapy groups for 
no complications versus any number of complications, degree of freedom 1.
Table 4: All complications
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signiﬁ cant complications, three of which were similar in 
the two groups. Wound seroma needing more than three 
aspirations were more frequent in the targeted 
intraoperative radiotherapy group than in the external 
beam radiotherapy group, whereas RTOG score of 3 or 
4 was more frequent in the external beam radiotherapy 
group than in the targeted intraoperative radiotherapy 
group. The total rate of major toxicities was similar in the 
two groups.
The number of axillary recurrences (targeted 
intraoperative radiotherapy, four vs external beam 
radiotherapy, three) and uncontrolled local recurrences 
at the time of death (one in each group) were similar in 
the two groups.
At 4 years, there were six local recurrences in the 
intraoperative radiotherapy group and ﬁ ve in the external 
beam radiotherapy group. Figure 4 shows the results for 
the primary endpoint of local recurrence. Figure 4A is 
the Kaplan-Meier plot for the whole cohort and shows 
narrow 95% CIs. Figure 4B shows the two randomised 
groups. There was no signiﬁ cant diﬀ erence in the 
Kaplan-Meier estimate of local recurrence in the 
conserved breast between the targeted intraoperative 
radiotherapy and external beam radiotherapy groups at 
4 years (1·20%, 95% CI 0·53–2·71 vs 0·95%, 0·39–2·31; 
diﬀ erence between groups 0·25%, –1·04 to 1·54; log-
rank test, p=0·41). Figure 4C shows the annual hazard of 
local recurrence in the ﬁ rst 4 years and the expected peak 
of recurrence in the second and third year with 
overlapping CIs for the targeted intraoperative 
radiotherapy and external beam radiotherapy groups.
Discussion
This large, international randomised trial provides robust 
and mature evidence that substantiates previous ﬁ ndings 
showing that targeted intraoperative radiotherapy is safe. 
Rates of overall complications and major complications 
were similar in the targeted intraoperative radiotherapy 
and external beam radiotherapy groups. Although there 
was a higher risk of seroma needing aspiration in patients 
assigned to targeted intraoperative radiotherapy than in 
those assigned to conventional treatment, this event was 
more than compensated for by signiﬁ cantly lower 
radiotherapy-related complications in the targeted 
intraoperative radiotherapy group (RTOG toxicity grade 3 
or 4).
When the original sample size of 2232 was calculated, 
we based our estimate of 5-year local recurrence rate of 6% 
on the literature available in 1999.12,26 We chose the non-
inferiority margin as an absolute diﬀ erence of 2·5% 
because this seemed clinically acceptable to physicians and 
patients. However, during the past decade recurrence rates 
have substantially reduced. The recurrence rate in the 
control group of our trial was 0·95% at 3 years. It would be 
logical to extrapolate the 5-year local recurrence rate to 
1·5%, which is not unexpected. For example, in the UK 
Standardisation of Breast Radiotherapy (START) trial,29 
patients had a worse prognosis (eg, 36% had a tumour size 
of more than 2 cm vs 14% in TARGIT-A and 22% were 
node positive vs 17% in TARGIT-A) and were treated a few 
years before patients were in our trial. In the START trial, 
the recurrence rate at 5 years was 2·3%. Therefore the 
estimate of 1·5% for our trial is not unrealistic.
The absolute non-inferiority margin of 2·5% could still 
be deemed reasonable because a 2·5% diﬀ erence in local 
recurrence at 5 years would translate into a 0·625% 
diﬀ erence in mortality at 15 years (by use of the 4:1 ratio 
reported in the analysis by the Early Breast Cancer 
Trialists’ Collaborative Group30), a magnitude that could 
be considered acceptable.31 In fact, two patient preference 
studies32,33 have suggested that the median additional 
increase that would be accepted in exchange for the 
convenience of a single treatment dose is 2·5%.
Thus, with a background recurrence rate at 5 years 
of only 1·5%, a trial for testing a non-inferiority margin 
of 2·5% with 80% power and 95% conﬁ dence needs a 
sample size of only 585 (table 6).34 In our trial of 
2232 patients, the number of patients with a median 
follow-up of 4 years was 862 and the number with a 
median follow-up of 3 years was 1514, well above the 
required 585 who already have a median follow-up of 
4·5 years. Studies of temporal distribution of local 
recurrence suggest that this period covers the peak 
hazard of local recurrence that occurs between 
Targeted intraoperative radiotherapy 
(n=1113)
External beam radiotherapy 
(n=1119)
p value
Haematoma needing surgical evacuation 11 (1·0%) 7 (0·6%) 0·338
Seroma needing more than three aspirations 23 (2·1%) 9 (0·8%) 0·012
Infection needing intravenous antibiotics or surgical intervention 20 (1·8%) 14 (1·3%) 0·292
Skin breakdown or delayed wound healing* 31 (2·8%) 21 (1·9%) 0·155
RTOG toxicity grade of 3 or 4† 6 (0·5%) 23 (2·1%) 0·002
Major toxicity‡ 37 (3·3%) 44 (3·9%) 0·443
Data are number of patients (%). RTOG=Radiation Therapy Oncology Group. *Some of the patients in the ﬁ rst three rows (haematoma needing surgical evacuation, seroma 
needing more than three aspirations, infection needing intravenous antibiotics or surgical intervention) could be included in the fourth row (skin breakdown or delayed 
wound healing). †No patient had grade 4 toxicity. ‡Deﬁ ned as skin breakdown or delayed wound healing and RTOG toxicity grade of 3 or 4).
Table 5: Clinically signiﬁ cant complications
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2–3 years after surgery,35 thus it is arguable that our 
results do have the maturity of follow-up in large 
enough numbers to draw cautious yet reasonable 
conclusions about eﬃ  cacy.
The local recurrence rate in the targeted intraoperative 
radiotherapy group was not signiﬁ cantly diﬀ erent from 
that in the external beam radiotherapy group (1·2% vs 
0·95%, p=0·41 at 4 years). As previously mentioned, the 
number of patients needed for testing a non-inferiority 
margin of 2·5% with 80% power and 95% conﬁ dence 
(n=585) have indeed completed a median 4·5 years of 
follow-up (minimum 3·6 years). One could therefore 
conclude that the targeted intraoperative radiotherapy 
approach is non-inferior in terms of eﬃ  cacy to control 
local recurrence in selected patients covering the period 
at maximum hazard for such events. Our results have 
established a clinically relevant non-inferiority with a 
margin of 1·5%.
Furthermore, in the fourth year, with 739 patients at 
risk, there was no local recurrence in either group, 
suggesting that our results are robust. The results 
conform to the idea that the peak hazard of local 
recurrence has passed by year 4.
To cater for a wide level of equipoise, our design was 
pragmatic with restrictions for age (≥45 years) and 
tumour size (preferably smaller than 3·5 cm) kept to a 
minimum, and no restrictions for grade and nodal status. 
At the outset, each centre speciﬁ ed these options in a 
treatment policy document. Allowing clinicians to be 
liberal in their intended inclusion criteria increased 
appeal and encouraged wider participation, yet led to a 
fairly homogeneous low risk patient sample, which 
showed an unsurprising conservatism among 
participating clinicians in this pragmatic trial.36
Biologically, these results challenge two very diﬀ erent 
dogma, ﬁ rst that whole breast radiotherapy is necessary 
in this group of patients, and, second, that the traditional 
radiation dose (much higher than targeted intraoperative 
radiotherapy) is essential for eﬀ ective tumour control.
Another interesting biological paradox is that the 
proportional risk reduction achieved by radiotherapy is 
the same whether the margins are positive, narrow, or 
wide, although the absolute reduction diﬀ ers. Of the 
breast-conserving trials that have tested the eﬀ ect of 
radiotherapy, patients in most trials,30 including National 
Surgical Adjuvant Breast and Bowel Project (NSABP) 
B06,37 underwent less extensive surgery than did patients 
in the Milan III trial.38 The recurrence rate in the control 
group of the Milan III trial, in which the tumour 
dimensions were smaller and excision was substantially 
wider than in other trials, was low (8·8% vs 24–27% in 
other trials). Nevertheless, radiotherapy reduced the 
recurrence rate even further and at the same proportional 
rate as it did in other trials. If local recurrence were caused 
by residual disease only, then radiotherapy should have 
aﬀ ected a much larger proportional reduction in those 
patients with positive margins or less extensive surgery; 
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Figure 4: Local recurrence in the conserved breast
(A) Survival free of local recurrence in the conserved breast in entire cohort. Shaded area represents 95% CIs. 
(B) Survival free of local recurrence in the conserved breast; all patients in the two randomised groups. (C) Annual 
hazards of local recurrence. Error bars represent 95% CIs. There were no recurrences in years 1 or 4. These graphs (A, 
B, and C) are restricted to 4 years because less than 420 (<20%) patients have a follow-up beyond this point; 
however, all patients (with a maximum follow-up of 10 years) are included in the analysis, as recommended by 
Pocock and colleagues.28
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but radiotherapy is as eﬀ ective in patients with negative 
margins, suggesting that this modality of treatment might 
have an eﬀ ect on the tumour microenvironment as well.5
The notion that some of the beneﬁ t from radiotherapy 
could result from a favourable eﬀ ect on the tumour 
microenvironment5 has been substantiated by 
translational research during targeted intraoperative 
radiotherapy.39 In this study, the wound ﬂ uid collected in 
the 24 h after surgical-wide local excision of cancer 
stimulated breast cancer cell lines to proliferate, migrate, 
and invade into Matrigel (BD Biosciences, San Jose, CA, 
USA). By contrast, the ﬂ uid obtained from wounds that 
had received targeted intraoperative radiotherapy did not 
stimulate cancer cells.39
A delay in delivery of radiotherapy either because of 
long waiting lists or because chemotherapy is given 
ﬁ rst, could jeopardise its eﬀ ectiveness.40 A recent large 
study41 in 18 050 patients has shown that timeliness 
does make an important diﬀ erence. If radiotherapy is 
delivered intraoperatively, it would avoid a temporal 
miss42 and enable the shortest possible interval between 
surgical resection of the cancer and accurate delivery 
of radiotherapy.
Mathematical models of radiotherapy43 suggest that a 
smaller number of well targeted doses of radiotherapy are 
probably more eﬀ ective than fractionated radiotherapy, 
which accords with the results of the START trial.29 
Additionally, the dose fall-oﬀ  with the Intrabeam treatment 
mimics the decreasing tumour cell density with increasing 
distance from the border of the macroscopic tumour. This 
dose distribution led to a novel target volume theory, the 
sphere of equivalence, for targeted intraoperative 
radiotherapy treatment.24 The model suggests that within 
such a sphere of equivalence24 around the intraoperative 
radiotherapy applicator, local control should be equivalent 
to that achieved by a course of fractionated radiotherapy. 
The beneﬁ cial eﬀ ect of targeted intraoperative radiotherapy 
on tumour microenvironment might enlarge such a 
sphere of equivalence.44
Although the traditional doses of fractionated 
radiation are much higher than the dose given with 
targeted intraoperative radiotherapy, the radiobiology of 
single doses under these circumstances is interestingly 
diﬀ erent. First, the radiation from Intrabeam (50 kV) 
has been shown to have an increased relative biological 
eﬀ ectivity (RBE) of 1·5–2·0, so the biological dose is 
much higher than the physical dose. Also, this RBE 
paradoxically increases with depth so that the clinically 
relevant dose fall-oﬀ  is less steep than is suggested 
from the mere physical dose distribution.21,24,45,46 Second, 
the intraoperative dose is given at the earliest possible 
time and within a short period. Therefore, there is no 
loss of dose because of tumour cell proliferation 
between surgery and the initiation of radiotherapy, and 
between the fractions of a fractionated course of 
radiotherapy. We previously reported24 that within the 
limits of the currently available radiobiological models, 
the dose of 20 Gy at the applicator surface is equivalent 
to a fractionated dose of 70 Gy.
There are several other trials of partial breast irradiation 
that use various techniques, including the ELIOT,47 
NSABP-B39, GEC ESTRO, and Hungarian trials.48 The 
ELIOT trial47 is the only other trial that uses single fraction 
intraoperative radiotherapy and a mobile linear accelerator 
that generates electrons at various energy levels. While 
the radiotherapy with targeted intraoperative treatment is 
given from within the breast with minimum additional 
dissection of the breast, the ELIOT technique47 requires 
the breast tissue to be dissected oﬀ  the skin and the chest 
wall and brought together for irradiation from outside the 
breast. The other trials use well-established techniques 
such as radioactive interstitial implants, intensity 
modulated and three-dimensional conformal radiotherapy, 
and interstitial balloon devices. Like TARGIT-A, all these 
trials are aimed at testing the idea of partial breast 
irradiation as an alternative to whole breast irradiation.
The implications of our results for day-to-day clinical 
practice will be aﬀ ected by emerging data from these trials, 
as well as the individual circumstances of the patient. 
Furthermore, we need longer term follow-up of our own 
trial to monitor the clinical appearance of new primary 
tumours outside the index quadrant or delayed recurrences 
inside the index quadrant. If the results of these trials 
reﬂ ect our results then the range of techniques available 
will mean that clinicians and patients will have a choice 
and could make individualised decisions based on the 
evidence available for each technique, patient preference, 
local resources, and professional expertise. We wish to 
urge caution while applying these results to clinical 
practice; although targeted intraoperative radiotherapy 
For more information about 
the NSABP-B39 trial see http://
www.nsabp.pitt.edu/B-39.asp
For more information about 
the GEC ESTRO trial see http://
www.apbi.uni-erlangen.de/
outline/outline.html
Background recurrence rate Recurrence rate in the experimental 
group (background plus non-
inferiority margin of 2·5%)
Total sample size required 
for 80% power and 
95% conﬁ dence
Median follow-up of this 
sample size in the TARGIT-A 
trial at present (months)
Expected 10 years ago 6% 8·5% 2232 25·3
Expected following recent publications (eg, START trial29) 3% 5·5% 1151 43·0
Actually found in the external beam radiotherapy group 
of the TARGIT-A trial
1·5% 4% 585 54·0
With a background recurrence rate of 1·5%, we need only 585 patients in total, which already have a median follow up of 54 months (4·5 years), long enough to draw reasonable conclusions (reference 35 and 
EAST, Cytel Statistical Software version 5, 2007).
Table 6: Sample size calculations for diﬀ erent scenarios
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provides eﬀ ective local control in the period of peak hazard 
(ﬁ rst 4 years), the results are valid only for patients with the 
clinicopathological features similar to those in this trial.
In addition to the obvious beneﬁ ts of completing all the 
necessary radiotherapy in a single session at the time of 
surgery, targeted intraoperative radiotherapy almost 
completely avoids irradiation of the intrathoracic 
structures such as the heart, lung, and oesophagus.21 
Consequently, the damage to these structures, which can 
occur even with modern external beam radiotherapy,49 
will have been avoided. We will monitor late cardiac 
toxicity in these patients to assess whether it is indeed 
lower in the targeted intraoperative radiotherapy group 
than in the external beam radiotherapy group.
A crucial issue in understanding this trial centres on 
the beneﬁ ts to the patient and the eﬀ ect on the workload 
of a radiotherapy centre. Treatment of patients with 
breast cancer accounts for about a third of the workload 
of radiotherapy departments in some parts of the world 
and contributes substantially to the unacceptable waiting 
lists seen in many oncology departments worldwide. In 
countries such as the UK where the waiting list for 
postoperative radiotherapy could rapidly diminish with 
use of targeted intraoperative radiotherapy, we estimate 
savings of around £15 000 000 (US$23 000 000) a year.5
When making decisions about which operation to 
choose, the main factors women are concerned about are 
tumour recurrence, the need for radiation therapy, and 
speed of recovery.50 Consequently, because the deﬁ nitive 
treatment with radiation can be completed at the time of 
the surgery or shortly afterwards in a single session with 
targeted intraoperative radiotherapy, two of the patients’ 
major concerns are immediately addressed, and perhaps 
fewer patients should feel obliged to choose mastectomy 
over breast-conserving surgery either because they live 
far away from a radiotherapy facility51 or to avoid 
prolonging their treatment. Furthermore, since the risk 
of local recurrence with targeted intraoperative 
radiotherapy is similar to that with conventional external 
beam radiotherapy, then this approach should eﬀ ectively 
deal with all three of the major concerns of women with 
breast cancer.
Our results bring us closer to a scenario in which a 
patient with early breast cancer might complete all her 
local treatment, surgical excision, sentinel lymph node 
biopsy, and radiotherapy at one or two visits, without 
having to stay overnight in a hospital bed. Together with 
the developments in adjuvant systemic therapy, these 
advances could substantially reduce the eﬀ ect of a breast 
cancer diagnosis and treatment on a woman’s life.
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